ReviewFrontiers in oral health2026
Nanomaterial-based strategies for oral biofilm management: functionalized implants and targeted delivery systems.
Review in Frontiers in oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biofilm-associated infections, particularly peri-implantitis, threaten the long-term success of dental implants, and conventional debridement or chemotherapy often fails against mature biofilms. Nanomaterials offer multifunctional strategies to control infection while supporting osseointegration. This mini-review (2015-2025) summarizes nanomaterial-based approaches for managing implant-associated oral biofilms, including passive surface functionalization, active delivery systems, externally triggered therapies, and host-directed osteoimmunomodulation. Their potential should be interpreted in light of evidence maturity, safety-especially for ROS-based modalities-and long-term tribological and manufacturing limitations. We also highlight practical selection by disease stage and host risk, while emphasizing key translational gaps, particularly validation in mixed-species biofilms and long-term biocompatibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.